Findings

What do systematic reviews say?

4 questions · 4 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

Terlipressin vs placebo or no intervention

Serious adverse events · people with hepatorenal syndrome

Terlipressin showed no clear difference in serious adverse events compared with placebo or no intervention (low certainty).

1 finding from 1 review

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.91 [0.68, 1.21]
9 studies · 534 participants
Low

Terlipressin vs other vasoactive drugs

Serious adverse events · people with cirrhosis and hepatorenal syndrome

It is very uncertain whether terlipressin changes serious adverse events compared with other vasoactive drugs (very low certainty).

1 finding from 1 review

Terlipressin versus other vasoactive drugs for hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 0.96 [0.88, 1.06]
474 participants
Very low

Terlipressin vs placebo or no intervention

Serious adverse events: cardiovascular events · people with hepatorenal syndrome

Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty).

1 finding from 1 review

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 7.26 [1.7, 31.05]
4 studies · 234 participants
Low

Terlipressin vs other vasoactive drugs

Non‐serious adverse events: diarrhoea or abdominal pain, or both · people with cirrhosis and hepatorenal syndrome

It is very uncertain whether terlipressin changes non‐serious adverse events: diarrhoea or abdominal pain, or both compared with other vasoactive drugs (very low certainty).

1 finding from 1 review

Terlipressin versus other vasoactive drugs for hepatorenal syndrome 2017 · Cochrane Headline outcomes only
RR 3.5 [1.19, 10.27]
221 participants
Very low